BCL2A1 and Langerhans cell histiocytosis: We investigated the ability of these agents (VBL alone or the combination of AraC and 2CdA) to decrease BCL2A1 expression and subsequently the survival of Mo-DCs from LCH patients by flow cytometry (Figure 3 and Table 2).